Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants

Mostrar otras versiones (1)

The recent emergence of multiple SARS-CoV-2 variants has caused considerable concern due to reduced vaccine efficacy and escape from neutralizing antibody therapeutics. It is therefore paramount to develop therapeutic strategies that inhibit all known and future SARS-CoV-2 variants. Here we report t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wirnsberger, Gerald, Monteil, Vanessa, Eaton, Brett, Postnikova, Elena, Murphy, Michael, Braunsfeld, Benedict, Crozier, Ian, Kricek, Franz, Niederhöfer, Janine, Schwarzböck, Alice, Breid, Helene, Jimenez, Anna Sanchez, Bugajska-Schretter, Agnes, Dohnal, Alexander, Ruf, Christine, Gugenberger, Romana, Hagelkruys, Astrid, Montserrat, Nuria, Holbrook, Michael R., Oostenbrink, Chris, Shoemaker, Robert H., Mirazimi, Ali, Penninger, Josef M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452097/
https://www.ncbi.nlm.nih.gov/pubmed/34545368
http://dx.doi.org/10.1101/2021.09.10.459744

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452097/
https://www.ncbi.nlm.nih.gov/pubmed/34545368
http://dx.doi.org/10.1101/2021.09.10.459744

Ejemplares similares